Related references
Note: Only part of the references are listed.The Bromodomain: A New Target in Emerging Epigenetic Medicine
Steven G. Smith et al.
ACS CHEMICAL BIOLOGY (2016)
MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies
E. Hessmann et al.
ONCOGENE (2016)
The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models
P. L. Garcia et al.
ONCOGENE (2016)
Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
Katrin Liffers et al.
TARGETED ONCOLOGY (2016)
SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin
Seong Joon Park et al.
TUMOR BIOLOGY (2016)
A New Way Forward in Cancer Drug Discovery: Inhibiting the SWI/SNF Chromatin Remodelling Complex
Giovanna Zinzalla
CHEMBIOCHEM (2016)
Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment
Yinshi Huang et al.
CLINICAL CANCER RESEARCH (2016)
CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer
Mark L. McCleland et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer
Domenico Ciliberto et al.
PANCREATOLOGY (2016)
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
Alison M. Kurimchak et al.
Cell Reports (2016)
Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity
Shiv K. Singh et al.
EMBO JOURNAL (2015)
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
Simone Meidhof et al.
EMBO MOLECULAR MEDICINE (2015)
Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation
Nilotpal Roy et al.
GENES & DEVELOPMENT (2015)
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
Christine M. Fillmore et al.
NATURE (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Acetylation site specificities of lysine deacetylase inhibitors in human cells
Christian Scholz et al.
NATURE BIOTECHNOLOGY (2015)
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Richard A. Moffitt et al.
NATURE GENETICS (2015)
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
Pawel K. Mazur et al.
NATURE MEDICINE (2015)
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kimberly H. Kim et al.
NATURE MEDICINE (2015)
Targeting BET bromodomains for cancer treatment
Marie Jung et al.
EPIGENOMICS (2015)
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Agnieszka K. Witkiewicz et al.
NATURE COMMUNICATIONS (2015)
Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery
Celeste B. Greer et al.
CELL REPORTS (2015)
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients
Michela Tassara et al.
BLOOD (2014)
EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells
Bryson W. Katona et al.
CANCER BIOLOGY & THERAPY (2014)
Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer
Jian Shi et al.
CANCER CELL (2014)
Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi et al.
MOLECULAR CELL (2014)
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
Sarah K. Knutson et al.
PLOS ONE (2014)
BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma
Joydeep Bhadury et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects
Daniel Neureiter et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
Bjoern Chapuy et al.
CANCER CELL (2013)
Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS
Takashi Yoshioka et al.
GYNECOLOGIC ONCOLOGY (2013)
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naive patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
K. Mross et al.
BRITISH JOURNAL OF CANCER (2012)
A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2012)
Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib
Anja Lachenmayer et al.
JOURNAL OF HEPATOLOGY (2012)
Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
Amir Avan et al.
MOLECULAR CANCER THERAPEUTICS (2012)
BET domain co-regulators in obesity, inflammation and cancer
Anna C. Belkina et al.
NATURE REVIEWS CANCER (2012)
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
Georg Feldmann et al.
CANCER BIOLOGY & THERAPY (2011)
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
Masashi Kanai et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
The Polycomb complex PRC2 and its mark in life
Raphael Margueron et al.
NATURE (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
NFAT-Induced Histone Acetylation Relay Switch Promotes c-Myc-Dependent Growth in Pancreatic Cancer Cells
Alexander Koeenig et al.
GASTROENTEROLOGY (2010)
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma
Adam D. Toll et al.
HUMAN PATHOLOGY (2010)
EP300-a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas
Soeren Torge Mees et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Jiahuai Tan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
Ron Epelbaum et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2010)
Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells
R. P. Sahu et al.
BRITISH JOURNAL OF CANCER (2009)
Biomarkers for predicting clinical responses to HDAC inhibitors
Lindsay Stimson et al.
CANCER LETTERS (2009)
Isoform-specific histone deacetylase inhibitors: The next step?
Sriram Balasubramanian et al.
CANCER LETTERS (2009)
E-Cadherin Regulates Metastasis of Pancreatic Cancer In Vivo and Is Suppressed by a SNAIL/HDAC1/HDAC2 Repressor Complex
Johannes von Burstin et al.
GASTROENTEROLOGY (2009)
Role of the polycomb protein EED in the propagation of repressive histone marks
Raphael Margueron et al.
NATURE (2009)
Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase Enhancer of Zeste Homologue 2
Andrei V. Ougolkov et al.
CLINICAL CANCER RESEARCH (2008)
Phase II trial of curcumin in patients with advanced pancreatic cancer
Navneet Dhillon et al.
CLINICAL CANCER RESEARCH (2008)
The sunset of somatic genetics and the dawn of epigenetics: a new frontier in pancreatic cancer research
Gwen Lomberk et al.
CURRENT OPINION IN GASTROENTEROLOGY (2008)
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors
Lillian L. Siu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors
Martin Haefner et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Histone deacetylases and cancer
M. A. Glozak et al.
ONCOGENE (2007)
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells
Takashi Kumagai et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors:: A clinical and translational study
Pamela Muenster et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products
Ajaikumar B. Kunnumakkara et al.
CANCER RESEARCH (2007)
Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway
Mao Li et al.
CANCER RESEARCH (2007)
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
D. A. Richards et al.
ANNALS OF ONCOLOGY (2006)
Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells
ST Nawrocki et al.
CANCER RESEARCH (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid
C Pilatrino et al.
CANCER (2005)
Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription
K Balasubramanyam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex
R Cao et al.
MOLECULAR CELL (2004)
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
SR Hingorani et al.
CANCER CELL (2003)
Share Paper
